David Huang

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Rachel Thijssen, Luyi Tian, Mary Ann Anderson, Christoffer Flensburg, Andrew Jarratt, Alexandra L Garnham, Jafar S Jabbari, Hongke Peng, Thomas E Lew, Charis E Teh, Quentin Gouil, Angela Georgiou, Tania Tan, Tirta M Djajawi, Constantine S Tam, John F Seymour, Piers Blombery, Daniel HD Gray, Ian J Majewski, Matthew E Ritchie, et al.

Journal article  |  2022  |  BLOOD

Venetoclax (VEN) inhibits the prosurvival protein BCL2 to induce apoptosis and is a standard therapy for chronic lymphocytic leuke..

What Next for Singlet Fission in Photovoltaics? The Fate of Triplet and Triplet-Pair Excitons

Rohan J Hudson, Alexandra N Stuart, David M Huang, Tak W Kee

Journal article  |  2022  |  JOURNAL OF PHYSICAL CHEMISTRY C

Exciton multiplication through singlet fission (SF) has the potential to surpass the detailed-balance efficiency limit of single-j..

Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK Dependent Cell Death

Sylvain Garciaz, Andrew A Guirguis, Sebastian Muller, Fiona C Brown, Yih-Chih Chan, Ali Motazediani, Caitlin L Rowe, James A Kuzich, Kah Lok Chan, Kevin Tran, Lorey Smith, Laura MacPherson, Brian Liddicoat, Enid YN Lam, Tatiana Caneque, Marian L Burr, Veronique Litalien, Giovanna Pomilio, Mathilde Poplineau, Estelle Duprez, et al.

Journal article  |  2022  |  CANCER DISCOVERY

UNLABELLED: Cancer cell metabolism is increasingly recognized as providing an exciting therapeutic opportunity. However, a drug th..

Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL

Piers Blombery, Thomas E Lew, Michael A Dengler, Ella R Thompson, Victor S Lin, Xiangting Chen, Tamia Nguyen, Ashish Panigrahi, Sasanka M Handunnetti, Dennis A Carney, David A Westerman, Constantine S Tam, Jerry M Adams, Andrew H Wei, David CS Huang, John F Seymour, Andrew W Roberts, Mary Ann Anderson

Journal article  |  2022  |  BLOOD

The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (..

Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing

Luyi Tian, Jafar S Jabbari, Rachel Thijssen, Quentin Gouil, Shanika L Amarasinghe, Oliver Voogd, Hasaru Kariyawasam, Mei RM Du, Jakob Schuster, Changqing Wang, Shian Su, Xueyi Dong, Charity W Law, Alexis Lucattini, Yair David Joseph Prawer, Coralina Collar-Fernandez, Jin D Chung, Timur Naim, Audrey Chan, Chi Hai Ly, et al.

Journal article  |  2021  |  GENOME BIOLOGY

A modified Chromium 10x droplet-based protocol that subsamples cells for both short-read and long-read (nanopore) sequencing toget..

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

Thomas E Lew, Victor S Lin, Edward R Cliff, Piers Blombery, Ella R Thompson, Sasanka M Handunnetti, David A Westerman, Bryone J Kuss, Constantine S Tam, David CS Huang, John F Seymour, Andrew W Roberts, Mary Ann Anderson

Journal article  |  2021  |  BLOOD ADVANCES

Covalent Bruton tyrosine kinase inhibitors (BTKi's) and the B-cell lymphoma 2 (BCL2) inhibitor venetoclax have significantly impro..

BCL2 and MCL1 inhibitors for hematologic malignancies

Andrew W Roberts, Andrew H Wei, David CS Huang

Journal article  |  2021  |  BLOOD

BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in hematologic cancers and play important roles in their..

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Rachel Thijssen, Sarah T Diepstraten, Donia Moujalled, Edward Chew, Christoffer Flensburg, Melissa X Shi, Michael A Dengler, Veronique Litalien, Sarah MacRaild, Maoshan Chen, Natasha S Anstee, Boris Reljic, Sarah S Gabriel, Tirta M Djajawi, Chris D Riffkin, Brandon J Aubrey, Catherine Chang, Lin Tai, Zhen Xu, Thomas Morley, et al.

Journal article  |  2021  |  BLOOD

Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemi..

PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling

Bing Yao, Tao Gui, Xiangwei Zeng, Yexuan Deng, Zhi Wang, Ying Wang, Dongjun Yang, Qixiang Li, Peipei Xu, Ruifeng Hu, Xinyu Li, Bing Chen, Jin Wang, Ke Zen, Haitao Li, Melissa J Davis, Marco J Herold, Hua-Feng Pan, Zhi-Wei Jiang, David CS Huang, et al.

Journal article  |  2021  |  GENOME MEDICINE

BACKGROUND: Aberrant changes in epigenetic mechanisms such as histone modifications play an important role in cancer progression. ..

Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Donia M Moujalled, Fiona C Brown, Giovanna Pomilio, Natasha S Anstee, Veronique Litalien, Ella R Thompson, Thomas Morley, Sarah MacRaild, Chong C Chua, SeBastien Banquet, Maia Chanrion, Ana-Leticia Maragno, Marie Schoumacher, Marco J Herold, Guillaume Lessene, Olivier Geneste, David CS Huang, Andrew W Roberts, Piers Blombery, Andrew Wei

Conference Proceedings  |  2020  |  BLOOD

Background: Recent randomized trials have demonstrated improvements in overall survival (OS) for the BCL-2 inhibito..